FOXRIDGEPLANNEDCOMMUNITIESBusiness Directories,Company Directories

Company Name: Corporate Name:	FOXRIDGEPLANNEDCOMMUNITIES
Company Title:	Lee Saylor
Company Description:
Keywords to Search:
Company Address:	1135AirbaseRoad,MOUNTAIN HOME,ID,USA
ZIP Code: Postal Code:	83647
Telephone Number:	2082783670 (+1-208-278-3670)
Fax Number:
Website:	leesaylor. com
Email:
USA SIC Code(Standard Industrial Classification Code):	653118
USA SIC Description:	Real Estate
Number of Employees:
Sales Amount:
Credit History: Credit Report:
Contact Person:
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
FIRST CLASS INC
MEALS ON WHEELS
AFFORDABLE FURNITURE

Next company profile:
SCOTT STAN - SCOTTS DESERT SUN REALTY
HAIR REFLECTIONS
PIZZA HUT

Company News:

FDA Approves First Gene Therapies to Treat Patients with Sickle Cell . . .
Today, the U S Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell
Revolutionary breakthrough: FDA approves CASGEVY, the first . . . - PubMed
Recently, Casgevy, the first CRISPR Cas9-based gene therapy for SCD, has received breakthrough FDA approval
FDA approves cure for sickle cell disease, the first treatment to use . . .
The Food and Drug Administration on Friday approved a powerful treatment for sickle cell disease, a devastating illness that affects more than 100,000 Americans, the majority of whom are
Creating the World’s First CRISPR Medicine, for Sickle Cell Disease
The decision has ushered in a new era for sickle cell disease treatment — and marked the world’s first approval of a medicine based on CRISPR Cas9 gene-editing technology
Novel Gene Therapy Trial for Sickle Cell Disease Launches
UCSF Benioff Children’s Hospital Oakland is enrolling patients in an innovative clinical trial that seeks to cure sickle cell disease The trial is the first in the U S to apply non-viral CRISPR-Cas9 gene-editing technology in humans to directly correct the genetic mutation that causes the disease
First CRISPR Therapy Approved for Sickle Cell
In the last five years, numerous new disease-modifying drugs have been approved to reduce the symptoms of sickle cell disease, and more gene therapies are being tested in clinical trials, showing good results so far
Gene therapy for sickle cell disease: recent advances, clinical trials . . .
Gene therapy, by addressing the root genetic causes, offers a revolutionary alternative This article discusses the molecular mechanisms of SCD and β-thalassemia and highlights advancements in gene therapy, such as gene addition via lentiviral vectors and gene editing with CRISPR Cas9 technology
First U. S. trial uses non-viral CRISPR to correct sickle cell mutation
UCSF Benioff Children's Hospital Oakland is enrolling patients in an innovative clinical trial that seeks to cure sickle cell disease The trial is the first in the U S to apply non-viral
New sickle cell treatment approved
In an historic moment for the sickle cell community, we are delighted that the MHRA (The Medicines and Healthcare products Regulatory Agency) approved the gene therapy known as Casgevy (Exagamglogene autotemcel) for the treatment of sickle cell disorder
Casgevy and Lyfgenia: Two Gene Therapies Approved for Sickle Cell . . .
Two groundbreaking gene therapies have been approved for sickle cell disease Yale Medicine pediatric hematologist-oncologists explain the treatments